Seres Therapeutics
MCRB
152 hedge funds and large institutions have $2.12B invested in Seres Therapeutics in 2020 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 48 increasing their positions, 36 reducing their positions, and 18 closing their positions.
217% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 18
162% more call options, than puts
Call options by funds: $17.7M | Put options by funds: $6.75M
35% more funds holding
Funds holding: 113 → 152 (+39)
33% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 36
0.16% less ownership
Funds ownership: 4.91% → 4.74% (-0.16%)
13% less capital invested
Capital invested by funds: $2.42B → $2.12B (-$303M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$79.1M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$42.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$38.1M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$29.5M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$21.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$202M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$134M |
| 3 |
Renaissance Technologies
New York
|
-$8.08M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$3.78M |
| 5 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$3.44M |
MCRB Hedge Fund Activity: Q4 2020 in Review
152 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q4 2020, worth a combined $2.12B — down 13% from $2.42B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new MCRB positions and 18 closed out — a net gain of 39 holders — while 48 added to existing stakes and 36 trimmed.
The largest buyer was State Street, adding an estimated $79.1M. The largest seller was Flagship Pioneering, cutting an estimated $202M.
- 152 institutional investors held Seres Therapeutics (MCRB) as of Q4 2020, up from 113 in Q3 2020.
- Funds reported $2.12B of Seres Therapeutics stock for Q4 2020, down 13% quarter-over-quarter.
- 57 funds opened new Seres Therapeutics positions in Q4 2020 and 18 closed out, a net change of +39 holders.
- The largest Seres Therapeutics buyer in Q4 2020 was State Street, an estimated $79.1M added.
- The largest Seres Therapeutics seller in Q4 2020 was Flagship Pioneering, an estimated $202M sold.
Based on aggregated 13F filings for Q4 2020.